Evidence map›Paper›PMID 27341812›Full record

Trial reportTrials2016

Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial.

Claire A Surr, Rebecca E A Walwyn, Amanda Lilley-Kelly, Robert Cicero, David Meads, Clive Ballard, Kayleigh Burton, Lynn Chenoweth, Anne Corbett, Byron Creese and 13 more

Abstract readMulticenter StudyRandomized Controlled TrialPragmatic Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Exploring self-report and proxy-report quality-of-life measures for people living with dementia in care homes.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Practicality Assessment of the Improved ICT-Based Dementia Care Mapping Support System.American journal of Alzheimer's disease and other dementias
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Claire A SurrFaculty of Health and Social Sciences, Leeds Beckett University, Leeds, LS1 3HE, UK. c.a.surr@leedsbeckett.ac.uk.
Rebecca E A WalwynLeeds Institute for Clinical Trials Research, University of Leeds, Leeds, LS2 9PH, UK.
Amanda Lilley-KellyLeeds Institute for Clinical Trials Research, University of Leeds, Leeds, LS2 9PH, UK.
Robert CiceroLeeds Institute for Clinical Trials Research, University of Leeds, Leeds, LS2 9PH, UK.
David MeadsLeeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9LJ, UK.
Clive BallardWolfson Centre for Age Related Diseases, Kings College London, London, UK.
Kayleigh BurtonLeeds Institute for Clinical Trials Research, University of Leeds, Leeds, LS2 9PH, UK.
Lynn ChenowethUniversity of Technology, Sydney, NSW 2007, Australia.
Anne CorbettWolfson Centre for Age Related Diseases, Kings College London, London, UK.
Byron CreeseWolfson Centre for Age Related Diseases, Kings College London, London, UK.
Murna DownsSchool of Dementia Studies, University of Bradford, Bradford, BD7 1DP, UK.
Amanda J FarrinLeeds Institute for Clinical Trials Research, University of Leeds, Leeds, LS2 9PH, UK.
Jane FosseyPsychological Services, Oxford Health NHS Foundation Trust, Oxford, OX3 7JX, UK.
Lucy GarrodPsychological Services, Oxford Health NHS Foundation Trust, Oxford, OX3 7JX, UK.
Elizabeth H GrahamLeeds Institute for Clinical Trials Research, University of Leeds, Leeds, LS2 9PH, UK.
Alys GriffithsFaculty of Health and Social Sciences, Leeds Beckett University, Leeds, LS1 3HE, UK.
Ivana HollowayLeeds Institute for Clinical Trials Research, University of Leeds, Leeds, LS2 9PH, UK.
Sharon JonesSchool of Dementia Studies, University of Bradford, Bradford, BD7 1DP, UK.
Baber MalikFaculty of Health and Social Sciences, Leeds Beckett University, Leeds, LS1 3HE, UK.
Najma SiddiqiBradford District Care Foundation Trust, Bradford, UK.
Louise RobinsonInstitute for Aging and Health, University of Newcastle, Newcastle upon Tyne, NE1 7RU, UK.
Graham StokesBupa, London, UK.
Daphne WallaceSchool of Dementia Studies, University of Bradford, Bradford, BD7 1DP, UK.

Funding

Department of Health 11/15/13
6 · The paper itself

Abstract

backgroundUp to 90 % of people living with dementia in care homes experience one or more behaviours that staff may describe as challenging to support (BSC). Of these agitation is the most common and difficult to manage. The presence of agitation is associated with fewer visits from relatives, poorer quality of life and social isolation. It is recommended that agitation is treated through psychosocial interventions. Dementia Care Mapping™ (DCM™) is an established, widely used observational tool and practice development cycle, for ensuring a systematic approach to providing person-centred care. There is a body of practice-based literature and experience to suggests that DCM™ is potentially effective but limited robust evidence for its effectiveness, and no examination of its cost-effectiveness, as a UK health care intervention. Therefore, a definitive randomised controlled trial (RCT) of DCM™ in the UK is urgently needed. METHODS/

designA pragmatic, multi-centre, cluster-randomised controlled trial of Dementia Care Mapping (DCM™) plus Usual Care (UC) versus UC alone, where UC is the normal care delivered within the care home following a minimum level of dementia awareness training. The trial will take place in residential, nursing and dementia-specialist care homes across West Yorkshire, Oxfordshire and London, with residents with dementia. A random sample of 50 care homes will be selected within which a minimum of 750 residents will be registered. Care homes will be randomised in an allocation ratio of 3:2 to receive either intervention or control. Outcome measures will be obtained at 6 and 16 months following randomisation. The primary outcome is agitation as measured by the Cohen-Mansfield Agitation Inventory, at 16 months post randomisation. Key secondary outcomes are other BSC and quality of life. There will be an integral cost-effectiveness analysis and a process evaluation. DISCUSSION: The protocol was refined following a pilot of trial procedures. Changes include replacement of a questionnaire, whose wording caused some residents distress, to an adapted version specifically designed for use in care homes, a change to the randomisation stratification factors, adaption in how the staff measures are collected to encourage greater compliance, and additional reminders to intervention homes of when mapping cycles are due, via text message.

trial registrationCurrent Controlled Trials ISRCTN82288852 . Registered on 16 January 2014. Full protocol version and date: v7.1: 18 December 2015.

Indexed as

Clinical ProtocolsPatient-Centered CareCaregiversCost-Benefit AnalysisDementiaHumansOutcome Assessment, Health CareQuality of LifeSample SizeAgitationCare homesCluster-randomised controlled trialDementiaDementia Care MappingPerson-centred care

Identifiers

PMID27341812
PMCPMC4921015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.